Developer docs
API playgroundTry for free, no card

Search company profiles

DP Technology

Full company profile

uuid0000nj7

Namestring
DP Technology
Legal namestring
北京深势科技股份有限公司
Websiteurl
dp.tech
Company typeenum
Private
Founded yearint
2018
Descriptiontext

DP Technology (Beijing Deep Potential Technology Co., Ltd., 深势科技) is a private AI for Science company founded in 2018 and headquartered in Haidian, Beijing. The company builds AI-native scientific discovery infrastructure, anchored by its proprietary Deep Potential molecular dynamics models and the 深势·宇知 (DP Scientific Discovery Intelligence Engine). It serves scientists and R&D organizations in life sciences (drug design, hit discovery, molecular computation), materials science (new energy, batteries, advanced materials), and academic research (chemistry, physics, biology) across China and North America.

Its product architecture follows a platform-plus-modules model. The Bohrium (玻尔) ecosystem functions as the connective layer, providing scientific navigation, a journal library, and access to 20M+ active global scholars, while Lebesgue (勒贝格智算) handles intelligent computing and Uni-Lab (跃迁实验室) integrates software with laboratory hardware. On top of this platform, the company sells specialized applications: Hermite for drug computation, RiDYMO for high-quality hit discovery, Piloteye for materials science R&D, and SciMaster as a scientific AI agent. Compute orchestration is delivered through Nodes, Workspace, and Jobs, supporting elastic heterogeneous computing at the "大装置" (large-scale scientific facility) layer.

The business model combines recurring SaaS subscriptions (Bohrium platform access), enterprise AI solutions (customized for pharma and materials organizations), and project-based R&D services. The company is sales-led with dedicated business development, investor relations, and HR channels, supported by a hybrid distribution approach that pairs direct enterprise sales with self-serve platform access. Operating geographies span Beijing, Shanghai, Shenzhen, and Yibin in China, with a US subsidiary (Atombeat Inc., Jersey City, NJ) handling North American enterprise coverage. As of late 2025, the company has 101–250 employees and has raised over US$250 million cumulatively, including a US$114 million Series C in December 2025.

Short descriptiontext

DP Technology is a Beijing-based AI for Science company founded in 2018 that builds Deep Potential molecular dynamics models and a Bohrium platform serving pharmaceutical, materials science, and academic researchers with integrated literature, computation, and laboratory tools across China and North America.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersHaidian, China
HQ citystring
Haidian
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI for Science, drug discovery platform, molecular dynamics simulation, computational chemistry software, materials science R&D
Industry4 codes
1AI/ML Platforms for Drug Discovery & Experiment Optimization
CodeHLAGAJAOPrimaryYes
2Cheminformatics & Molecular Modeling / CADD
CodeHLAGAJAEPrimaryNo
3Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
CodeHLAGAJACPrimaryNo
4LLMOps & Generative AI Platforms (Prompt/Agent Orchestration, RAG)
CodeHDAEANADPrimaryNo
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)541715
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Commercial Physical & Biological Research8731
Product category
Scientific Computing Software
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1SaaS / Platform Subscriptions
TypeSubscription Recurring
Description

The company offers platform-based products including Bohrium (科学导航, 勒贝格智算), Hermite, RiDYMO, Piloteye, and Uni-Lab as subscription or license-based software products. The Bohrium Scholar platform covering 20M+ scholars suggests a platform/SaaS model with tiered access.

dp.tech
2R&D Services
TypeProfessional Services
Description

The company provides enterprise-level AI+ computing services and R&D services for life sciences (drug design, battery development) and materials science (new energy R&D, new materials R&D), likely structured as project-based or retainer engagements.

dp.tech
3Enterprise Solutions
TypeSubscription Recurring
Description

Customized enterprise-level AI solutions for organizations in life sciences and materials science sectors, combining software tools with computational infrastructure.

dp.tech
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 6 records shown
1Bohrium (玻尔)
Description

Scientific research platform and navigation system providing academic resources and research tools including journal library, scholar coverage, and workspace

dp.tech
+5 more records
Core offering1 text field

DP Technology builds an AI for Science platform that combines molecular simulation, scientific AI models, and laboratory automation to serve life sciences, materials science, and chemistry R&D. Its offerings include the Bohrium scientific navigation workspace, the Hermite drug design platform, the RiDYMO hit discovery platform, Piloteye for materials science, and the Uni-Lab laboratory integration system.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Reduced time-to-insight in drug design and materials discovery through AI-accelerated molecular dynamics simulation
+1 more record
Product overview1 text field

DP Technology operates as a unified platform-plus-modules architecture built on its proprietary 深势·宇知® (DP Scientific Discovery Intelligence Engine) as the foundational layer. The platform provides a Science as a Service intelligent research product and service matrix comprising 'reading documents, doing calculations, doing experiments' tools. The core Bohrium ecosystem includes 玻尔·科学导航 (Bohrium) for scientific navigation, 玻尔·勒贝格智算 for intelligent computing, and 玻尔·跃迁实验室 (Bohrium Transition Lab) for laboratory integration. Specialized applications include Hermite® for drug calculation, RiDYMO® for Hit discovery, and Piloteye® for materials science R&D. The SciMaster scientific AI agent system and supporting infrastructure (Uni-Lab, Jobs, Workspace, Nodes) complete the platform for fundamental research, life sciences, and materials science applications.

Product and service1 record
1Bohrium Scientific Navigation (玻尔·科学导航)
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-listed computational chemistry and molecular simulation company combining physics-based methods with AI/ML for drug and materials discovery — the closest Western analogue to DP Technology's Deep Potential simulation stack and Hermite/Piloteye product positioning.

TypeDirect peer
Description

AI drug discovery company applying knowledge graphs and ML to identify novel drug targets and treatments — comparable enterprise AI-for-drug-discovery business model serving pharma R&D organizations.

TypeDirect peer
Description

AI-driven drug discovery company combining high-throughput wet-lab experimentation with machine learning — comparable to DP Technology's integrated 'read-compute-experiment' workflow including Uni-Lab lab automation.

TypeDirect peer
Description

Shenzhen-based AI drug discovery company using physics-informed AI and high-performance computing for crystal structure prediction and molecular design — directly comparable to DP Technology as a Chinese AI-for-drug-discovery peer with global pharma customers.

TypeEmerging player
Description

AI-driven drug discovery company combining physics-based simulation with neural network potentials for small molecule design — closely comparable technical approach to DP Technology's Deep Potential architecture.

TypeDirect peer
Description

Hong Kong-headquartered AI-driven drug discovery company operating end-to-end from target identification to clinical-stage assets — overlaps with DP Technology's Hermite (computational drug design) and RiDYMO (Hit discovery) products.

TypeDirect peer
Description

AI platform for materials and chemicals R&D serving enterprise customers in batteries, alloys, and specialty chemicals — directly comparable to DP Technology's Piloteye materials science R&D software.

TypeDirect peer
Description

AI small molecule discovery company using deep learning for hit identification and lead optimization — overlaps with DP Technology's RiDYMO Hit discovery platform and AI-for-drug-discovery positioning.

TypeDirect peer
Description

AI-native pharma company using AI-driven drug design and active learning for small molecule discovery — directly comparable to DP Technology's life sciences stack (Hermite, RiDYMO).

TypeEmerging player
Description

China-based AI drug delivery and formulation company explicitly referenced in the company data as a peer — overlaps with DP Technology's AI-driven life sciences focus but with a narrower formulation/delivery niche.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors22 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DP Technology

Scientific Computing Softwaredp.tech

DP Technology is a Beijing-based AI for Science company founded in 2018 that builds Deep Potential molecular dynamics models and a Bohrium platform serving pharmaceutical, materials science, and academic researchers with integrated literature, computation, and laboratory tools across China and North America.

What DP Technology does

DP Technology (Beijing Deep Potential Technology Co., Ltd., 深势科技) is a private AI for Science company founded in 2018 and headquartered in Haidian, Beijing. The company builds AI-native scientific discovery infrastructure, anchored by its proprietary Deep Potential molecular dynamics models and the 深势·宇知 (DP Scientific Discovery Intelligence Engine). It serves scientists and R&D organizations in life sciences (drug design, hit discovery, molecular computation), materials science (new energy, batteries, advanced materials), and academic research (chemistry, physics, biology) across China and North America.

Its product architecture follows a platform-plus-modules model. The Bohrium (玻尔) ecosystem functions as the connective layer, providing scientific navigation, a journal library, and access to 20M+ active global scholars, while Lebesgue (勒贝格智算) handles intelligent computing and Uni-Lab (跃迁实验室) integrates software with laboratory hardware. On top of this platform, the company sells specialized applications: Hermite for drug computation, RiDYMO for high-quality hit discovery, Piloteye for materials science R&D, and SciMaster as a scientific AI agent. Compute orchestration is delivered through Nodes, Workspace, and Jobs, supporting elastic heterogeneous computing at the "大装置" (large-scale scientific facility) layer.

The business model combines recurring SaaS subscriptions (Bohrium platform access), enterprise AI solutions (customized for pharma and materials organizations), and project-based R&D services. The company is sales-led with dedicated business development, investor relations, and HR channels, supported by a hybrid distribution approach that pairs direct enterprise sales with self-serve platform access. Operating geographies span Beijing, Shanghai, Shenzhen, and Yibin in China, with a US subsidiary (Atombeat Inc., Jersey City, NJ) handling North American enterprise coverage. As of late 2025, the company has 101–250 employees and has raised over US$250 million cumulatively, including a US$114 million Series C in December 2025.

DP Technology firmographics

Firmographics
Name
DP Technology
Legal name
北京深势科技股份有限公司
Website
https://dp.tech
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
101–250 employees
Short description
DP Technology is a Beijing-based AI for Science company founded in 2018 that builds Deep Potential molecular dynamics models and a Bohrium platform serving pharmaceutical, materials science, and academic researchers with integrated literature, computation, and laboratory tools across China and North America.
Ownership category
akta.pro rank

DP Technology industry classification

Industry
Product category
Scientific Computing Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715), Scientific Research and Development Services (5417)
SIC
Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)
akta.pro primary industry
AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
akta.pro secondary industries
Cheminformatics & Molecular Modeling / CADD (HLAGAJAE), Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC), LLMOps & Generative AI Platforms (Prompt/Agent Orchestration, RAG) (HDAEANAD)

Keywords

  • AI for Science
  • Drug discovery platform
  • Molecular dynamics simulation
  • Computational chemistry software
  • Materials science R&D

Where DP Technology is headquartered

Location

Headquarters

HQ city
Haidian
HQ country
China
HQ region
Asia

Offices5 records

Markets served

DP Technology business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. SaaS / Platform Subscriptions: The company offers platform-based products including Bohrium (科学导航, 勒贝格智算), Hermite, RiDYMO, Piloteye, and Uni-Lab as subscription or license-based software products. The Bohrium Scholar platform covering 20M+ scholars suggests a platform/SaaS model with tiered access.
  2. R&D Services: The company provides enterprise-level AI+ computing services and R&D services for life sciences (drug design, battery development) and materials science (new energy R&D, new materials R&D), likely structured as project-based or retainer engagements.
  3. Enterprise Solutions: Customized enterprise-level AI solutions for organizations in life sciences and materials science sectors, combining software tools with computational infrastructure.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

DP Technology product offering

Product offering

Core offering

DP Technology builds an AI for Science platform that combines molecular simulation, scientific AI models, and laboratory automation to serve life sciences, materials science, and chemistry R&D. Its offerings include the Bohrium scientific navigation workspace, the Hermite drug design platform, the RiDYMO hit discovery platform, Piloteye for materials science, and the Uni-Lab laboratory integration system.

Product overview

DP Technology operates as a unified platform-plus-modules architecture built on its proprietary 深势·宇知® (DP Scientific Discovery Intelligence Engine) as the foundational layer. The platform provides a Science as a Service intelligent research product and service matrix comprising 'reading documents, doing calculations, doing experiments' tools. The core Bohrium ecosystem includes 玻尔·科学导航 (Bohrium) for scientific navigation, 玻尔·勒贝格智算 for intelligent computing, and 玻尔·跃迁实验室 (Bohrium Transition Lab) for laboratory integration. Specialized applications include Hermite® for drug calculation, RiDYMO® for Hit discovery, and Piloteye® for materials science R&D. The SciMaster scientific AI agent system and supporting infrastructure (Uni-Lab, Jobs, Workspace, Nodes) complete the platform for fundamental research, life sciences, and materials science applications.

Differentiator

Problem solved

Functional benefit

Brands

  • Bohrium (玻尔): Scientific research platform and navigation system providing academic resources and research tools including journal library, scholar coverage, and workspace
  • Hermite
  • RiDYMO
  • Uni-Lab
  • Piloteye
  • SciMaster

Products and services

  • Bohrium Scientific Navigation (玻尔·科学导航)

Quantifiable outcome

  • Reduced time-to-insight in drug design and materials discovery through AI-accelerated molecular dynamics simulation
  • +1 more outcomes

Companies that use DP Technology

Customer profile

Segments3 records

Ideal customer profiles3 records

DP Technology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

DP Technology partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

DP Technology competitors and assessment

Company assessment

Direct peers

  • Schrödinger: US-listed computational chemistry and molecular simulation company combining physics-based methods with AI/ML for drug and materials discovery — the closest Western analogue to DP Technology's Deep Potential simulation stack and Hermite/Piloteye product positioning.
  • BenevolentAI: AI drug discovery company applying knowledge graphs and ML to identify novel drug targets and treatments — comparable enterprise AI-for-drug-discovery business model serving pharma R&D organizations.
  • Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput wet-lab experimentation with machine learning — comparable to DP Technology's integrated 'read-compute-experiment' workflow including Uni-Lab lab automation.
  • XtalPi: Shenzhen-based AI drug discovery company using physics-informed AI and high-performance computing for crystal structure prediction and molecular design — directly comparable to DP Technology as a Chinese AI-for-drug-discovery peer with global pharma customers.
  • Insilico Medicine: Hong Kong-headquartered AI-driven drug discovery company operating end-to-end from target identification to clinical-stage assets — overlaps with DP Technology's Hermite (computational drug design) and RiDYMO (Hit discovery) products.
  • Citrine Informatics: AI platform for materials and chemicals R&D serving enterprise customers in batteries, alloys, and specialty chemicals — directly comparable to DP Technology's Piloteye materials science R&D software.
  • Atomwise: AI small molecule discovery company using deep learning for hit identification and lead optimization — overlaps with DP Technology's RiDYMO Hit discovery platform and AI-for-drug-discovery positioning.
  • Exscientia: AI-native pharma company using AI-driven drug design and active learning for small molecule discovery — directly comparable to DP Technology's life sciences stack (Hermite, RiDYMO).

Emerging players

  • Iambic Therapeutics: AI-driven drug discovery company combining physics-based simulation with neural network potentials for small molecule design — closely comparable technical approach to DP Technology's Deep Potential architecture.
  • METiS Therapeutics: China-based AI drug delivery and formulation company explicitly referenced in the company data as a peer — overlaps with DP Technology's AI-driven life sciences focus but with a narrower formulation/delivery niche.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

DP Technology social profiles

Digital presence

DP Technology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DP Technology leadership team

Management profile

Number of profiles

DP Technology subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

DP Technology funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DP Technology M&A and investment

M&A and investment

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DP Technology

What does DP Technology do?

DP Technology builds an AI for Science platform that combines molecular simulation, scientific AI models, and laboratory automation to serve life sciences, materials science, and chemistry R&D. Its offerings include the Bohrium scientific navigation workspace, the Hermite drug design platform, the RiDYMO hit discovery platform, Piloteye for materials science, and the Uni-Lab laboratory integration system.

Is DP Technology a public or private company?

DP Technology is a private company. It is classified as venture growth investor backed and is currently operating.

When was DP Technology founded?

DP Technology was founded in 2018. It employs 101 to 250 people.

Where is DP Technology based?

DP Technology is headquartered in Haidian, China, in the Asia region.

How does DP Technology make money?

Three revenue lines are on record. SaaS / Platform Subscriptions are the primary driver. The others are R&D Services and enterprise Solutions.

Who are DP Technology's main competitors?

Direct peers on record are Schrödinger, BenevolentAI, Recursion Pharmaceuticals, XtalPi, Insilico Medicine, Citrine Informatics, Atomwise and Exscientia. Emerging players are Iambic Therapeutics and METiS Therapeutics.

Does DP Technology have an API?

No public API is recorded for DP Technology.

What industry is DP Technology in?

DP Technology's product category is Scientific Computing Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAE, Cheminformatics & Molecular Modeling / CADD. Its NAICS code is 541714 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ChinaventureDialogue with Tian Jiangchuan: After Yushu, it's time to go to the poker table.Tian Jiangchuan, partner at Chuxin Capital, discussed her investment in Unitree Robotics, which returned over 700 times its initial investment. She explained the firm's tracking system and her intuition-based approach, and noted Unitree's overseas revenue and upcoming IPO.AETOSWireAnt Group launches AQ for Doctor, bringing an AI-powered workstation to millions of physiciansAnt Group upgraded its physician platform Haodf for Doctor into AQ for Doctor, an AI-powered workstation for physicians. The platform integrates with the AQ app, which has over 100 million users, and connects more than 300,000 verified physicians. It also opens the platform to hospitals, with Guangzhou Women and Children's Medical Center as the first partner.PedailyThe AI Battle of Peking University AlumniPeking University alumni are leading AI startups across enterprise, scientific, and embodied intelligence, with several going public on the Hong Kong Stock Exchange. Notable companies include Minglue Technology, Jishijiao, and Galaxy General, which has raised over 6.96 billion yuan. The university is building a sustainable innovation system to support early-stage projects.FinancialContent Business PageExcalipoint Therapeutics and DP Technology Enter into Strategic Partnership to Co-Develop Proprietary AI-Powered TCE Agentic PlatformExcalipoint Therapeutics and DP Technology have entered a strategic partnership to co-develop a proprietary AI agentic platform for T-cell engager (TCE) and multi-specific antibody discovery, integrating Excalipoint's TCE molecular libraries and experimental datasets with DP Technology's SciMaster and BioMaster AI agent suites. The platform aims to overcome key TCE development challenges by enabling predictive modeling of affinity and specificity, dynamic parameter balancing, and autonomous molecular design through a closed-loop Design-Build-Test-Learn cycle. The collaboration marks a milestone in Excalipoint's transformation into an AI-immersed biotech company, with the goal of reducing development timelines, lowering costs, and accelerating delivery of novel cancer and autoimmune therapeutics globally.Business Wire BlogExcalipoint Therapeutics and DP Technology Enter into Strategic Partnership to Co-Develop Proprietary AI-Powered TCE Agentic PlatformExcalipoint Therapeutics and DP Technology announced a strategic collaboration to co-develop a proprietary AI agentic platform for T-cell engager (TCE) and multi-specific antibody discovery, integrating Excalipoint's TCE molecular libraries and experimental data with DP Technology's SciMaster and BioMaster AI agent suites. The platform aims to address key bottlenecks in TCE development by using AI to balance efficacy and toxicity parameters, replacing traditional trial-and-error wet lab screening approaches. The collaboration marks a milestone in Excalipoint's transformation into an AI-immersed TCE developer, with plans to expand AI deployment across the full R&D workflow including target identification, pharmacology, toxicology, and clinical trial design.Tech in AsiaChina boosts state-backed funding for AI drug developersChina's government-linked investors are increasing funding for AI-driven drug developers as part of Beijing's technological self-sufficiency push, with Hangzhou-based METiS TechBio raising 400 million yuan (US$56 million) in series D funding led by state-backed funds. METiS's AI-designed drug MTS-004 for neurological disorders has completed Phase III trials and the company plans to seek regulatory approval in China while considering a Hong Kong IPO potentially raising up to US$200 million. Other Chinese AI drug firms including DP Technology and StoneWise have also received state-related funding, reflecting a broader recovery in biotech funding with increased focus on licensing deals and global competitiveness.Startuphealth2026 Funding Kicks Off with Global Momentum in AI, Diagnostics, and Digital Care | StartUp Health Insights: Week of Jan 6, 2026StartUp Health's first funding report of 2026 documents health innovation funding activity across 10 companies spanning China, Israel, India, the US, Japan, South Korea, and the UK during the first week of January, with raises fueling AI-driven research, cardiovascular care, cancer diagnostics, telehealth, and public health innovation. Notable rounds include DP Technology's 800M yuan ($114M) AI research platform funding led by Fortune Venture Capital and Beijing Jingguorui Equity Investment Fund, and Biobeat Technologies' $50M blood pressure monitoring funding led by Ally Bridge Group, OrbiMed Advisors, and Elevage Medical Technologies. The funding roundup captures a continuation of late-December investment momentum into the new year across digital health and medical technology sectors.Startuphealth2026 Funding Kicks Off with Global Momentum in AI, Diagnostics, and Digital CareMultiple health innovation companies across the globe announced funding rounds this week, spanning AI-driven research tools, diagnostics, digital health platforms, and medical monitoring technologies. DP Technology led with $114M raised for AI-accelerated scientific research, followed by Biobeat Technologies and Nanit each securing $50M for blood pressure and baby monitoring solutions respectively. The roundup covers 10 companies across eight countries—China, India, Israel, the US, UK, Japan, and South Korea—with funding ranging from $2.5M to $114M, reflecting continued investor interest in health technology startups.South China Morning PostAI-for-Science start-up DP Technology raises US$114 million in Series C roundBeijing-based AI-for-Science start-up DP Technology has raised US$114 million in a Series C funding round to expand its research and development capabilities and hire new talent. The investment was backed by a consortium of state-linked and venture capital firms, including Fortune Venture Capital and Lenovo Capital.PR NewswireRiDYMO® Designs Cyclic Peptide for "Undruggable" β-Catenin Target Within Two MonthsDP Technology's AI-driven drug discovery platform RiDYMO® successfully designed a cyclic peptide targeting the historically 'undruggable' β-catenin protein—a key player in cancer development—in just two months. The platform screened a library of over 10^12 cyclic peptides and macrocyclic molecules, testing 29 candidates of which 12 showed strong inhibition of protein-protein interactions, with compound 24 effectively disrupting the Wnt/β-catenin signaling pathway by blocking the β-catenin/BCL9 interaction. This breakthrough demonstrates the potential of AI-driven platforms to accelerate drug discovery for previously intractable targets and open new avenues for cancer treatment.